FDA Approves Scholar Rock's Isembyld for SMA in Patients 2+
SRRK has more than doubled off its 52-week low of $27.07.
Summary
The FDA approved Isembyld (apitegromab) for spinal muscular atrophy in patients aged 2 years and older. This is the first approval for Scholar Rock's lead asset and validates the company's muscle-targeting approach. The approval comes ahead of the September 30 PDUFA date, removing a major regulatory overhang. With a market cap near $6.7B and a cash runway into 2027, the company is now positioned to commercialize its first product. The label covers a broad SMA population, expanding the addressable market beyond the previously studied non-ambulatory patients. This follows the August 6 Q2 report that highlighted the upcoming PDUFA decision as the key catalyst.
Updates
· SEC 8-K — Scholar Rock was awarded a Rare Pediatric Disease Priority Review Voucher with the approval. The 8-K also furnished the press release and presentation slides, and scheduled a conference call for September 14 at 8:00 a.m. ET.
· Seeking Alpha — Shares jumped 12% in extended trading; commercial launch underway with shipments expected in days; investor call Monday at 8 a.m. ET will detail pricing and rollout.
At the time of this announcement, SRRK was trading at $55.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $27.07 to $61.76. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Reuters.